Novavax (FRA:NVV1) Cash Flow for Dividends: €0.0 Mil (TTM As of Mar. 2026)


FRA:NVV1 Novavax Inc FRA:NVV1
49 GF Score
Price €8.24
GF Value €3.37
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novavax Cash Flow for Dividends?

Novavax FRA:NVV1 +0.24% 49 Cash Flow for Dividends is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:NVV1 with a GF Score™ of 49/100 and a GF Value™ of €3.37 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Novavax's cash flow for dividends for the three months ended in Mar. 2026 was €0.0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Novavax Cash Flow for Dividends Related Terms

Novavax Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Novavax's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Cash Flow for Dividends Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Novavax Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:NVV1
49GF Score
Novavax Inc FRA:NVV1
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €0.0 Mil mean?
Novavax (FRA:NVV1) has a Cash Flow for Dividends of €0.0 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Novavax and its competitors.
Is Novavax's Cash Flow for Dividends too high?
Novavax's current Cash Flow for Dividends is €0.0 Mil. Overall, Novavax has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Cash Flow for Dividends compare to MPLT and COAG?
Novavax's Cash Flow for Dividends of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Novavax and its competitors. Novavax's current Cash Flow for Dividends is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (FRA:NVV1) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.37, compared to a current price of €8.24 — trading 144.5% above its estimated fair value. The current Cash Flow for Dividends is €0.0 Mil. Novavax's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Novavax (FRA:NVV1), the current Cash Flow for Dividends is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (FRA:NVV1) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of €8.24 is trading 144.5% above its estimated GF Value™ of €3.37. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for FRA:NVV1:

  • Cash Flow for Dividends: €0.0 Mil
  • GF Value™: €3.37 vs. price of €8.24 (144.5% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the FRA:NVV1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
49GF Score

Get the complete analysis for FRA:NVV1

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.24
Price
€3.37
GF Value